10-K: American Oncology Network Delists from Nasdaq, Reports Growth in 2024

American Oncology Network voluntarily delisted from Nasdaq, transitioned to OTCQX, and reported revenue growth driven by increased patient encounters and strategic initiatives in its 2024 10-K filing.

Summary

• American Oncology Network (AON) voluntarily delisted its Class A Common Stock and warrants from the Nasdaq Capital Market and commenced trading on the OTCQX Best Market.
• The company's obligation to file periodic reports with the SEC under Section 15(d) of the Exchange Act has been suspended, subject to filing its Form 10-K for the 2024 fiscal year.
• AON's revenue grew at a roughly 41% CAGR from 2019 to 2024.
• The global community oncology services market size is expected to grow to $81.33 billion in 2027, with a CAGR of 10.9%.
• The oncology pharmaceuticals market is expected to grow to $314 billion by 2026.
• As of December 31, 2024, AON's platform includes 37 practices across 20 states and the District of Columbia.
• AON has identified material weaknesses in its internal control over financial reporting.
• The top ten Network Practices generated approximately 59.3% of AON's revenue for the fiscal year ended December 31, 2024.
• AON's principal corporate offices are located in Fort Myers, Florida, where it leases approximately 9,500 square feet of office space that expires in 2038.
• As of December 31, 2024, AON employed approximately 1,914 employees, including approximately 266 physicians and advanced practice providers.
• The company completed a Class A Common Stock financing on November 12, 2024, raising $51 million before fees and expenses.
• AON's effective income tax rate was (10.15)% for the year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is revenue growth and expansion, the delisting from Nasdaq and material weaknesses in internal controls raise concerns.

Positives

• AON's revenue has grown at a roughly 41% CAGR from 2019 to 2024.
• The global community oncology services market is projected to reach $81.33 billion in 2027.
• AON completed a Class A Common Stock financing on November 12, 2024, raising $51 million.
• AON is expanding its national research platform to offer patients access to cutting-edge clinical trials within the community setting.

Negatives

• AON voluntarily delisted from Nasdaq.
• AON identified material weaknesses in its internal control over financial reporting.
• The company's obligation to file periodic reports with the SEC under Section 15(d) of the Exchange Act has been suspended.
• The AON PNC Loans and the associated restrictive covenants thereunder could adversely affect our financial condition and will restrict our ability to raise capital.

Risks

• AON needs to contract and form partnerships with Network Practices in order to execute its growth strategy.
• A significant portion of AON's revenue is derived from a limited number of health insurance and medical group companies.
• AON faces significant competition from other healthcare services providers.
• Reductions in government reimbursement rates or changes in the rules governing government healthcare programs could have a material adverse effect.
• A pandemic, epidemic or outbreak of an infectious disease could adversely affect AON's business.
• AON's business could be adversely affected by supply price increases, particularly with respect to intravenous and oral drug costs and shortages.
• AON relies on third-party information technology systems that could suffer from disruptions and data breaches.
• Some jurisdictions preclude AON from entering into non-compete agreements with physicians.
• Inflation may adversely affect AON by materially increasing its costs.

Future Outlook

AON anticipates adding more managed practices in the future across its markets through acquisitions and organic growth within existing practices.

Industry Context

The global community oncology services market is expected to grow significantly, presenting a substantial opportunity for AON to expand its services.

Comparison to Industry Standards

• The document mentions US Oncology Network, Inc. and OneOncology, Inc. as competitors, highlighting AON's differentiated management model that gives network physicians a high level of autonomy.
• The document does not provide specific details to global benchmarks.

Related Party Transactions

• The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Stockholder.
• The Company has operating leases for ten of the office facilities owned by employees of the Company.

Stakeholder Impact

• The delisting from Nasdaq may impact shareholder confidence and the stock's liquidity.
• The expansion of services and access to clinical trials could benefit patients.
• The focus on value-based care aims to provide high-quality, lower-cost care, benefiting patients, providers, and payors.

Next Steps

• AON plans to pursue accelerated growth through acquisition with a more aggressive approach towards M&A.
• AON plans to expand its national research platform.
• The Company is in the process of designing and implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies which led to the material weaknesses.

Key Dates

Keywords

oncology, healthcare, revenue, practices, patients, clinical, pharmacy, growth, market, physicians